Wechselwirkungen · Sildenafil Actavis
Sildenafil Actavis 25 mg film-coated tablets Sildenafil Actavis 50 mg film-coated tablets Sildenafil Actavis 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-211718 · Präparat HOS-154739
Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment the hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including sildenafil, is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-11-13T17:59:00Z · SHA-256 8d339cf63d7199374f2ece12de82d79c2afadc784f0e022556816c15588f8759 · Passage fb207357e01f6963af8ef0ba3724a31dffe7034c79512e41a6f13722046d8352 · Zeichen 5117–5564 im Abschnitt